<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To evaluate <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> in the elderly (people &gt; or = 60 yr) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Basal gastric acid secretion was prospectively determined in 228 consecutive patients with symptomatic <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> who had upper gastrointestinal endoscopy and were diagnosed with either pyrosis alone (n = 98), erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo> (n = 87), or <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (n = 43) </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Patients &gt; or = 60 yr (n = 66) had significantly more esophageal <z:e sem="disease" ids="C0151785" disease_type="Disease or Syndrome" abbrv="">mucosal disease</z:e> (erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>) than patients &lt; 60 yr (n = 162)--81% versus 47% (p = 0.000002, Fisher's exact test) </plain></SENT>
<SENT sid="3" pm="."><plain>Furthermore, 87% of patients &gt; or = 70 yr had esophageal <z:e sem="disease" ids="C0151785" disease_type="Disease or Syndrome" abbrv="">mucosal disease</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>For each decade from &lt; 30 yr to &gt; or = 70 yr, there was a significant increase in esophageal <z:e sem="disease" ids="C0151785" disease_type="Disease or Syndrome" abbrv="">mucosal disease</z:e> (p = 0.002; chi 2 test, 23.96); however, there were no significant differences in severity of pyrosis symptoms or in mean basal acid output for each decade </plain></SENT>
<SENT sid="5" pm="."><plain>When 146 of the 228 patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> were given enough <z:chebi fb="10" ids="8776">ranitidine</z:chebi> (mean, 630 mg/d; range, 300-3000 mg/d) for the relief of <z:hpo ids='HP_0000001'>all</z:hpo> pyrosis symptoms and healing of <z:hpo ids='HP_0000001'>all</z:hpo> esophageal <z:e sem="disease" ids="C0151785" disease_type="Disease or Syndrome" abbrv="">mucosal disease</z:e>, there were no significant differences in <z:chebi fb="10" ids="8776">ranitidine</z:chebi> therapy between each decade </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Elderly patients with pyrosis symptoms severe enough to require upper gastrointestinal endoscopy have <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> with more esophageal <z:e sem="disease" ids="C0151785" disease_type="Disease or Syndrome" abbrv="">mucosal disease</z:e> (erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>) than patients &lt; 60 yr, and like younger patients, may require markedly increased doses of <z:chebi fb="10" ids="8776">ranitidine</z:chebi> as large as 2400 mg/d for effective therapy </plain></SENT>
</text></document>